Overview: Total PSA TestIntroduction: The Total PSA Test measures total PSA to diagnose prostate cancer, causing difficulty urinating. Aligned with 2023 ASCO guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected prostate cancer.
Other Names: Total PSA Assay, Prostate-Specific Antigen Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: PSA testing began in the 1980s with prostate cancer research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures total PSA to diagnose prostate cancer, guides treatment, and evaluates patients with difficulty urinating.
Test Parameters: 1. Total PSA Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of difficulty urinating or prostate symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document difficulty urinating, prostate enlargement, or family history of prostate cancer. Include current medications, especially 5-alpha-reductase inhibitors.
Consent: Written consent required, detailing the tests purpose, prostate cancer implications, and risks of sample collection.
Procedural Considerations: Uses immunoassays to measure total PSA levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for prostate cancer diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or recent prostate manipulation can affect results. Medications may lower PSA levels.
Clinical Significance: Elevated total PSA suggests prostate cancer, guiding biopsy or imaging. Normal levels may require free PSA testing.
Specialist Consultation: Consult a urologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Free PSA, prostate biopsy, or MRI to confirm prostate cancer diagnosis.
Test Limitations: Non-specific for prostate cancer; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Prostate Cancer Guidelines, 2023; Journal of Urology, Catalona WJ, 2022.
